Core Points - CENTOGENE N.V. announced the voting results of its 2024 Annual General Meeting, with shareholders approving all proposals [1] - Shareholders extended the deadline for preparing the Dutch statutory annual accounts and board report for the financial year ended December 31, 2023, and appointed Ernst & Young Accountants LLP as the external auditor for the financial year ended December 31, 2024 [2] - The revised compensation structure for the Company's Supervisory Board was adopted, and the Management Board's authorization to issue shares and grant rights was extended [2] Company Overview - CENTOGENE's mission focuses on providing data-driven answers for rare and neurodegenerative diseases, integrating multiomic technologies with the CENTOGENE Biodatabank [3] - The company has built a network of approximately 30,000 active physicians and operates ISO, CAP, and CLIA certified multiomic reference laboratories in Germany [4] - The CENTOGENE Biodatabank includes data from over 850,000 patients across more than 120 countries, with over 70% of patients being of non-European descent [4] - CENTOGENE has supported over 50 collaborations with pharmaceutical partners to accelerate drug discovery and development [5]
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting